NCT02787837Unknown不适用
Prospective Multi-Centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.
Centro Nacional de Investigaciones Oncologicas CARLOS III24 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2014年5月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 220
- 试验地点
- 24
- 主要终点
- To validate the independent prognostic value of the gene-expression signature from peripheral blood described by Olmos et al (Lancet Oncol 2012) on overall survival of mCRPC patients
研究概览
简要总结
PROSABI is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with abiraterone
详细描述
This study is a prospective biomarker study of patients with mCRPC undergoing treatment with abiraterone as standard of care treatment. The participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male age ≥ 18 years
- •Histologically confirmed adenocarcinome of the prostate
- •ECOG Performance Status ≤ 2
- •Castration resistance must be documented with surgical or medical castration with serum testosterone < 50 ng/mL (< 2.0 nM).
- •Men diagnosed with at least one metastatic lesion on CT or bone scan.
- •Documented biochemical and/or radiographic progression to previous treatment according to PCWG2 criteria.
- •Patients who are candidates for standard of care treatment with abiraterone acetate: 1000 mg every 24 hours plus prednisone 5 mg every 12 hours.
- •Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy and/or radical prostatectomy.
- •Acceptable hematological, hepatic and renal functions.
- •Acceptable haematological, hepatic and renal functions.
排除标准
- •Previous cancer diagnosis, except those patients who had a localized malignant tumour and who are five years cancer-free or those diagnosed with skin cancers (of non-melanoma type) or excised in situ carcinomas.
- •Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data
结局指标
主要结局
To validate the independent prognostic value of the gene-expression signature from peripheral blood described by Olmos et al (Lancet Oncol 2012) on overall survival of mCRPC patients
时间窗: Initially 48 months, currently 60 months
次要结局
- To analyze the prognostic value of early changes in the gene-expression signature described by Olmos et al(Initially 48 months, currently 60 months)
- To correlate the presence of somatic and/or germinal mutations with the outcomes of these patients(Initially 48 months, currently 60 months)
- To validate the prognostic value of classical nomograms designed to assess the outcomes of mCRPC patients in these patients(Initially 48 months, currently 60 months)
- To analyze the prognostic value of AR splicing variants, serum chromogranine and serum testosterone levels measured by ultrasensitive method in these both cohorts of patients(Initially 48 months, currently 60 months)
- To compare the prognostic value of the gene-expression signature described by Olmos et al versus the gene-expression signature described by Ross et al (Lancet Oncol, 2012)(Initially 48 months, currently 60 months)
- To analyze the prognostic value of TMPRSS2-ERG rearrengement and PTEN loss in these cohorts(Initially 48 months, currently 60 months)
- To analyze the prognostic value of the gene-expression signature described by Olmos et al on biochemical and radiological progression-free survival(Initially 48 months, currently 60 months)
研究者
研究点 (24)
Loading locations...
相似试验
Unknown
不适用
PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.Advanced Prostate CancerCastration ResistantEnzalutamideNCT02922218Centro Nacional de Investigaciones Oncologicas CARLOS III187
Unknown
不适用
PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.Advanced Prostate CancerCabazitaxelDocetaxelNCT02362620Centro Nacional de Investigaciones Oncologicas CARLOS III402
Unknown
不适用
PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.Advanced Prostate CancerCastration ResistantRadium 223NCT02925702Centro Nacional de Investigaciones Oncologicas CARLOS III161
已完成
不适用
A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer ParticipantsProstatic NeoplasmsNCT02813408Janssen Pharmaceutica N.V., Belgium226
进行中（未招募）
2 期
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by EnzalutamideCastration-resistant Prostate CancerProstate CancerNCT03700099Instituto do Cancer do Estado de São Paulo30